Neoplasms

Symptoms and General Pathology

All Conditions

Neoplasms, Unknown Primary

Neoplasm Metastasis

Neoplastic Processes

PET-CT

Gedske Daugaard

Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT cost-effective?

Patients who fulfill the international definition of unknown primary tumors can be included, except:

* Young men (\<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
* Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
* Women with adenocarcinoma in lymph nodes in the axilla will not be included.

Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors

PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors

Rigshospitalet, Denmark

Associate professor

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Digestive System Diseases

Blood and Lymph Conditions

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Nervous System Diseases

Nutritional and Metabolic Diseases

Musculoskeletal Diseases

Rare Diseases

Syndrome

Nasopharyngeal Carcinoma

Esophageal Neoplasms

Leukemia

Cholangiocarcinoma

Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Skin Neoplasms

Prostatic Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Stomach Neoplasms

Sarcoma

Carcinoma, Renal Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Multiple Myeloma

Neoplasms, Plasma Cell

Adenomatous Polyposis Coli

Urinary Bladder Neoplasms

Vaginal Neoplasms

Gastrointestinal Stromal Tumors

Liver Neoplasms

Neuroendocrine Tumors

Thyroid Nodule

Mesothelioma

Mesothelioma, Malignant

Duodenal Neoplasms

Mouth Neoplasms

Thymoma

Thymus Neoplasms

Central Nervous System Neoplasms

Testicular Neoplasms

Kidney Neoplasms

Anus Neoplasms

Nervous System Neoplasms

Endometrial Neoplasms

Salivary Gland Neoplasms

Gallbladder Neoplasms

Oropharyngeal Neoplasms

Bile Duct Neoplasms

Nasopharyngeal Neoplasms

Carcinoma

Urethral Neoplasms

Laryngeal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Hypopharyngeal Neoplasms

Intestinal Neoplasms

Penile Neoplasms

Ureteral Neoplasms

Peritoneal Neoplasms

Paranasal Sinus Neoplasms

Lip Neoplasms

Paraproteinemias

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Male Urogenital Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Gonadal Disorders

Neoplasms, Connective and Soft Tissue

Rectal Neoplasms

Intestinal Diseases

Rectal Diseases

Urologic Neoplasms

Urologic Diseases

Colonic Diseases

Head and Neck Neoplasms

Esophageal Diseases

Ken Cowan, MD

Michelle M Desler, MS

Jeannie Robbins

Noelle Beauchemin, MD

Sandy Allten, RN

Erik Harris, MD

Sandra Allten, RN,OCN,CCRP

Kellie Hyde

Luke Hazen

Joseph Meschi, MD

Amanda Baker, CCRP

Joseph T Meschi, MD

Neil Sharma, MD

Breck Hunnicutt, RN BSN CCRC

Betsy Glowinski

Anuj Agarwala, MD

Michael Zlomke, MD

Tammy Johnson, CBPN

Karrie Cheeseman, BSN, RN

Mukund Nadipuram, MD

Kelley Aldrich

Addison Tolentino, MD

Judy Bosley

Qiwei Gai, MD

Johanna DiMento, MD

Lynn Downey, RHIT, CTR

Zubeena Mateen, MD

Lauren Keppeler

Bret Friday, MD, PhD

Bret Friday, MD

Andrea Berget

Anne Silva-Benedict, MD

Molly Kidwell

Juliet Gyamfua Appiah, MD

Adam Gott

Justin Thomas, MD

Melissa Lundbeck Kaptanian, MD

Mandy Bartlett, RN

Joan Meese

Cynthia Montgomery, RN

Rahib C Fahed, MD

Irena Popa, MD

Lisa Kosmacek

Irfan Vaziri, MD

Russell Smith, MD

Liza Brandes

Kathryn Bartz

Aru Panwar, MD

Whitney Goldner, MD

Michelle M Desler

Beth Brundage, RN, ORC

Aqeel Gillani, MD

Kenneth Manning, MD

Rebekah Bullard

Joni Buechler-Price, MD

Tammie Mlodozyniec

Pamela Brewer

Patanit Watanaboonyakhet, MD

Carla Larch

Shruti Trehan, MD

William Spanos, MD

Adam Voss

Tonya Welch

Allan D Eisemann, MD

Anna Mason, CCRP

Darlene Blanchard, MD

Abigail Hecker

Seth Joppe

Hassan Tahsildar, MD

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2project.org) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred \& Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically-interoperable and easily-customizable cancer data resource which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals.

The iCaRe2 provides: (i) a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; (ii) utilization of standard vocabulary and data elements; and (iii) the ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.

The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries:

(i) the Pancreatic Cancer Collaborative Registry (PCCR) established in 2001, (ii) the Breast Cancer Collaborative Registry (BCCR) established in 2006, (iii) the Thyroid Cancer Collaborative Registry (TCCR) established in 2006, and (iv) the Great Plains Health Informatics Database (GPHID) established in 2011, to enroll subjects who have no personal history of cancer diagnosis at the time of enrollment.

At present, this framework has been incrementally expanded to include the Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal \& Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), and Auxiliary Cancer Registry (ACR).

The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. It was felt that these latter models implied that the registry or network would assume control of an individual Center's database. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. It was also recognized that for this model to be successful, it is essential to have a standardized approach to data collection (patient information and biospecimen annotation) and reporting. A confederation would also encourage participation of any interested Center, irrespective of its size or location. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data.

Questionnaire: baseline and follow up. Blood: At enrollment (approximately 2 tablespoons) and at other time points during your routine care visits, typically before or after treatment changes. This amount will not exceed 15 tablespoons per year; donation is optional.

Urine: At enrollment and follow up appointments if there is an active study (optional).

Access to leftover tissue: release a portion of leftover tissue collected and saved from surgery/biopsy.

Tissue procurement and banking of excess biological materials. This includes but not limited to tumor tissue and/or metastatic cancer tissue and/or paraffin embedded tissue collected and saved from biopsy and/or surgery done in the past or future, from registry participants.

Integrated Cancer Repository for Cancer Research

All data and/or specimen request have to be made to the Principal Investigator of the center and follow the Human Subject Protection guidelines and policy.

This is a registry with biobank and accrual will continue indefinitely

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors	NCT00269373	Unknown Primary...	PET-CT	18 Years - 75 Years	Rigshospitalet, Denmark
Integrated Cancer Repository for Cancer Research	NCT02012699	Pancreatic Canc... Thyroid Cancer Lung Cancer Esophageal Canc... Thymus Cancer Colon Cancer Rectal Cancer Gastrointestina... Anal Cancer Bile Duct Cance... Duodenal Cancer Gallbladder Can... Gastric Cancer Liver Cancer Small Intestine... Peritoneal Surf... Familial Adenom... Lynch Syndrome Bladder Cancer Kidney Cancer Penile Cancer Prostate Cancer Testicular Canc... Ureter Cancer Urethral Cancer Hypopharyngeal ... Laryngeal Cance... Lip Cancer Oral Cavity Can... Nasopharyngeal ... Oropharyngeal C... Paranasal Sinus... Nasal Cavity Ca... Salivary Gland ... Skin Cancer Central Nervous... Central Nervous... Mesothelioma Breast Cancer Leukemia Melanoma Sarcoma Unknown Primary... Multiple Myelom... Ovarian Cancer Endometrial Can... Vaginal Cancer Neuroendocrine ... Plasma Cell Dys... Healthy Control		19 Years - 110 Years	University of Nebraska
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors	NCT00269373	Unknown Primary...	PET-CT	18 Years - 75 Years	Rigshospitalet, Denmark

Spots Global Cancer Trial Database for unknown primary tumor